168 related articles for article (PubMed ID: 38491904)
1. Enhancing Tumor Immunotherapy by Multivalent Anti-PD-L1 Nanobody Assembled via Ferritin Nanocage.
Liu M; Jin D; Yu W; Yu J; Cao K; Cheng J; Zheng X; Wang A; Liu Y
Adv Sci (Weinh); 2024 May; 11(20):e2308248. PubMed ID: 38491904
[TBL] [Abstract][Full Text] [Related]
2. ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy.
Jia D; Zhao S; Liu H; Zhan X; Zhou Z; Lv M; Tang X; Guo W; Li H; Sun L; Zhong Y; Tian B; Yuan D; Tang X; Fan Q
Int J Biol Macromol; 2024 Jun; 269(Pt 2):132058. PubMed ID: 38704065
[TBL] [Abstract][Full Text] [Related]
3. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
[TBL] [Abstract][Full Text] [Related]
4. Tackling Esophageal Squamous Cell Carcinoma with ITFn-Pt(IV): A Novel Fusion of PD-L1 Blockade, Chemotherapy, and T-cell Activation.
Xin Q; Wang D; Wang S; Zhang L; Liang Q; Yan X; Fan K; Jiang B
Adv Healthc Mater; 2024 Apr; 13(11):e2303623. PubMed ID: 38142309
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
6. Nanobody-Ferritin Conjugate for Targeted Photodynamic Therapy.
Liu M; Zhu Y; Wu T; Cheng J; Liu Y
Chemistry; 2020 Jun; 26(33):7442-7450. PubMed ID: 32166771
[TBL] [Abstract][Full Text] [Related]
7. Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4.
Hao S; Xu S; Li L; Li Y; Zhao M; Chen J; Zhu S; Xie Y; Jiang H; Zhu J; Wu M
BMC Cancer; 2022 Oct; 22(1):1092. PubMed ID: 36284271
[TBL] [Abstract][Full Text] [Related]
8. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
9. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
10. The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy.
Liu J; Zhao Z; Qiu N; Zhou Q; Wang G; Jiang H; Piao Y; Zhou Z; Tang J; Shen Y
Nat Commun; 2021 Apr; 12(1):2425. PubMed ID: 33893275
[TBL] [Abstract][Full Text] [Related]
12. Blocking the PD-1-PD-L1 axis by a novel PD-1 specific nanobody expressed in yeast as a potential therapeutic for immunotherapy.
Xian Z; Ma L; Zhu M; Li G; Gai J; Chang Q; Huang Y; Ju D; Wan Y
Biochem Biophys Res Commun; 2019 Nov; 519(2):267-273. PubMed ID: 31495493
[TBL] [Abstract][Full Text] [Related]
13. Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).
Wen B; Zhao L; Wang Y; Qiu C; Xu Z; Huang K; Zhu H; Li Z; Li H
Prep Biochem Biotechnol; 2020; 50(3):252-259. PubMed ID: 31799894
[TBL] [Abstract][Full Text] [Related]
14. Long-term combined blockade of CXCR4 and PD-L1 with in vivo reassembly for intensive tumor interference.
Deng ZW; Yang JK; Qiu KJ; Zhang TJ; He Z; Wang N; Chen XG; Liu Y
J Control Release; 2024 Jun; 370():453-467. PubMed ID: 38697315
[TBL] [Abstract][Full Text] [Related]
15. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
16. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
[TBL] [Abstract][Full Text] [Related]
17. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.
Zhu L; Li J; Guo Z; Kwok HF; Zhao Q
J Nanobiotechnology; 2022 Dec; 20(1):521. PubMed ID: 36496381
[TBL] [Abstract][Full Text] [Related]
18. Second near-infrared photothermal-amplified immunotherapy using photoactivatable composite nanostimulators.
Sun H; Yu T; Li X; Lei Y; Li J; Wang X; Peng P; Ni D; Wang X; Luo Y
J Nanobiotechnology; 2021 Dec; 19(1):433. PubMed ID: 34930269
[TBL] [Abstract][Full Text] [Related]
19. Anti-human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation.
Bridoux J; Broos K; Lecocq Q; Debie P; Martin C; Ballet S; Raes G; Neyt S; Vanhove C; Breckpot K; Devoogdt N; Caveliers V; Keyaerts M; Xavier C
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33003481
[TBL] [Abstract][Full Text] [Related]
20. A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy.
Li M; Zhao D; Yan J; Fu X; Li F; Liu G; Fan Y; Liang Y; Zhang X
ACS Nano; 2024 May; 18(20):12870-12884. PubMed ID: 38727063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
